Lung Cancer Treatment: Antibody-Drug Conjugates

Recent data shows that telehealth is comparable to quality of life to in-person visits for patients with advanced non–small cell lung cancer.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Adagrasib significantly improved responses among patients with KRASG12C-mutated locally advanced or metastatic non–small cell lung cancer.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

A Prescription Drug User Fee Act target action date of September 25, 2024, has been set for the application of pembrolizumab plus chemotherapy in advanced mesothelioma.

AFM24 combined with atezolizumab has received a fast track designation from the FDA for treating advanced/metastatic non-small cell lung cancer without activating EGFR mutations.